Deadpool20mg
Blend of Cartalax, BPC-157, TB-500 (TB4)
Deadpool Blend Canada — 20 mg Lyophilized Vials
Recovery Blend
Also known as Cartalax 10mg + BPC-157 5mg + TB-500 5mg
Deadpool is a research blend supplying cartalax 10mg, BPC-157 5mg, and TB-500 5mg in a single 20mg vial. Supplied strictly for laboratory research use within Canada. Not for human or veterinary use.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Deadpool is a research blend supplying cartalax, BPC-157, and TB-500 in a single vial.
Each component is separately studied in tissue-repair research; the combination itself has no published literature.
Deadpool combines a short peptide bioregulator associated with cartilage models (cartalax, Ala-Glu-Asp) with two peptides that recur in tissue-repair research. BPC-157 is a synthetic fragment of a gastric protein studied for angiogenic and inflammatory signaling. TB-500 corresponds to an active region of thymosin beta-4, studied for actin binding and cell migration.
The combination is a formulation choice. References below are drawn from the component literature.
The components entered research independently: BPC-157 through gastric-protein fragment work, thymosin beta-4 through actin-sequestering protein research, and cartalax through the short-peptide bioregulator programme.
The blend has no separate development history and is a supplier formulation.
Research relevant to Deadpool is the sum of its components: angiogenic and inflammatory signaling, actin-binding and cell migration, and short-peptide regulation in connective-tissue models. No study has evaluated this specific three-component combination.
2 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on angiogenic or inflammatory. This heading marks where Deadpool Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Bock-Marquette 2004, Ashapkin 2020. The work appeared in Nature. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on connective, tissue or bioregulator. This heading marks where Deadpool Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Bock-Marquette 2004. The work appeared in Nature. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 5 primary papers published between 1993 and 2020 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Deadpool Blend, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Deadpool Blend is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under angiogenic and inflammatory signaling (BPC-157), actin-binding and cell-migration research (TB-500) and connective-tissue bioregulator models (cartalax).
The 5 papers cited on this page, published between 1993 and 2020 (1 in animal models and 1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
The lot code printed on the vial matches the code on the certificate for Deadpool Blend. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Deadpool Blend in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
Deadpool Blend is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.
Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Deadpool. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(5):313–327.
PubMedGastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 21(6):976–983.
PubMedThymosin beta4 accelerates wound healing. J Invest Dermatol 113(3):364–368.
PubMedThymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432(7016):466–472.
PubMedGene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Body Protection Compound Pentadecapeptide · 10 mg BPC-157 is a synthetic peptide derived from a fragment of a naturally occurring gastric protein. It is produced for laboratory research and studied within controlled experimental environments.
10 mgBPC-CA-26F-1099.765%
10.98 mg / 10 mg
$39.95CAD
